SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

The Sperm Whale is drawing intense attention as a highly volatile meme coin, with the community actively debating whether it is a legitimate high-reward opportunity or a classic pump-and-dump scheme. Investors are closely monitoring its price action and social media momentum, with some hoping for a massive rebound while others warn of the inherent risks of unverified, rapid-fluctuation tokens.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

Aircoin is trending as investors rally around its "PvE" (Player vs. Environment) narrative on Solana, emphasizing community-led supply locks and a long-term, non-hype approach. The community is highly active in promoting the token's growth, citing its consistent grind and strategic vision as key drivers for its recent momentum.

$FUUU is a Solana-based memecoin that was launched on http://Pump.fun in March 2024. The project is themed around the Rage Guy character, a figure that originated in the rage comic era of the late 2000s and became widely recognized across internet culture. Following the launch, the original developer discontinued involvement with the token. At that point, the CTO team assumed responsibility for coordinating ongoing community efforts around the project.  The stated purpose of $FUUU is cultural rather than financial. It is designed as a “culture coin” that highlights Rage Guy as a symbolic and relatable figure. The character’s expression of frustration, commonly represented by the text “FFFFUUUU,” reflects emotions that are often tied to both cryptocurrency markets and everyday experiences. By building a token around this meme, the project aims to preserve a recognizable piece of internet history within a blockchain context.  Unlike projects that emphasize detailed roadmaps, technical milestones, or defined utility, $FUUU positions itself as a lighthearted and entertainment-driven token. There are no team allocations, no taxes, and no embedded promises of profit or financial return. The coin is intended solely for cultural engagement, community participation, and meme creation. Holders and community members are encouraged to contribute through content, discussion, and the continued use of Rage Guy imagery, but there are no obligations or formal expectations tied to the token.  The CTO team provides organizational support, and back end support such as hiring an artist and creatin websites, the community drives activity associated with the project. This includes creating and sharing memes, maintaining discussion channels, and ensuring the Rage Guy character remains present in contemporary internet culture. The project does not claim utility beyond its role as a culture coin, and its sustainability depends entirely on voluntary participation and ongoing community interest.  From a transparency standpoint, the on-chain parameters of the token are publicly visible. These include the mint authority status, freeze authority, liquidity details (whether burned or locked), and circulating supply information. Any locked or burn addresses are disclosed for the purpose of supporting accurate supply tracking on external platforms.  Rage Guy ($FUUU) should not be viewed as an investment. The token has no intrinsic value and provides no rights, revenue, or guarantees to holders. As with all cryptoassets, trading is highly risky, and participants are advised to conduct their own research and fully understand the risks involved. The project’s focus remains cultural preservation and community expression rather than financial

FUUUUUUUUUUUUUU

FUUU is trending as a highly speculative, high-volatility meme token that has captured community attention through rapid price swings and aggressive social media promotion. Investors are actively debating whether the token represents a genuine breakout opportunity or a high-risk pump-and-dump scheme, with many treating the asset as a collective 'degen' gamble against broader market frustrations.

Nova Ltd. provides metrology solutions for the semiconductor manufacturing industry. Its product portfolio includes dimensional metrology, modeling & software, materials metrology, and chemical metrology. The company was founded by Giora Dishon and Moshe Finarov in May 1993 and is headquartered in Rehovot, Israel.

Nova Ltd

Nova Ltd is capturing investor interest as a key player in the semiconductor capital expenditure cycle, with the community highlighting its strong position in AI-driven chip infrastructure and advanced metrology. Recent bullish analyst coverage and optimism surrounding its earnings trajectory are fueling active discussions about the stock's long-term growth potential and momentum.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is experiencing significant volatility and trading activity as investors debate the impact of mainnet roadmap developments, institutional partnerships with regulated banks, and the ongoing airdrop distribution. Community sentiment is deeply divided, with many debating the trade-offs between the network's privacy-focused ZK-proof technology and its integration with major cloud providers, while others focus on its relationship to the broader Cardano ecosystem.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is generating significant momentum as the community champions a revival of OG internet culture through the creation of classic rage comics on the Solana blockchain. Investors and supporters are actively focused on building mindshare and emphasizing long-term conviction, viewing the project as a foundational leader for the broader meme sector.

NEOS ETF Trust - NEOS S&P 500 High Income ETF

NEOS S&P 500 High Income ETF

SPYI is trending as investors aggressively build positions in high-yield income ETFs to capture consistent monthly payouts while seeking tax-efficient alternatives to traditional dividend stocks. Community sentiment remains largely focused on the strategy of reinvesting dividends into these income-generating vehicles to compound returns during market volatility.

Direxion Shares ETF Trust - Direxion Daily FTSE China Bear 3X ETF

Direxion Daily FTSE China Bear 3X Shares

YANG is trending as investors weigh China's aggressive stimulus measures and market-wide rallies against the lingering threat of escalating trade tensions and potential US tariff actions. The community is actively debating whether to capitalize on the recent Chinese equity breakout or prepare for a sharp reversal as market participants closely monitor the sustainability of the current rally amidst persistent macroeconomic skepticism.

BWX Technologies, Inc. engages in the supply and provision of nuclear components and products. It operates through the Government Operations and Commercial Operations segments. The Government Operations segment manufactures naval nuclear reactors, including the related nuclear fuel, for the U.S. Naval Nuclear Propulsion Program for use in submarines and aircraft carriers. The Commercial Operations segment fabricates commercial nuclear steam generators, nuclear fuel, fuel handling systems, pressure vessels, reactor components, heat exchangers, tooling delivery systems, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level waste and supplies nuclear-grade materials and precisely machined components for nuclear utility customers. The company was founded by Stephen Wilcox and George Babcock in 1867 and is headquartered in Lynchburg, VA.

BWX Technologies Inc

BWX Technologies is trending following a strong quarterly earnings report that topped analyst estimates, fueling community optimism around its critical role in naval nuclear propulsion and its expanding footprint in the small modular reactor market. Investors are closely tracking its backlog growth and long-term contracts as the company positions itself as a central player in the broader nuclear energy renaissance.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing significant community attention as it attempts to break through major long-term resistance levels, with many traders debating whether it will decouple from Bitcoin and initiate a broader breakout. Discussion is polarized between bullish sentiment regarding upcoming network upgrades and technical momentum, and skeptical voices questioning the token's long-term utility and historical price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q1 Earnings Forecast for CAPR Issued By HC Wainwright

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a...

<ul class="summary-bullets"><li>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on Friday's selloff.</li><li>B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares.</li><li>The Food and Drug Administration has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22.</li></ul>Shares of Capricor Therapeutics (CAPR) fell 9% on Friday after the company reported a wider-than-expected Q4 loss but Wall Street analysts raised their price targets on the stock over hopes for an approval of the company’s lead candidate.On the company’s fourth-quarter (Q4) <a href="https://stocktwits.com/news-articles/markets/equity/capricor-reports-wider-quaterly-loss-than-expected-but-all-eyes-are-on-deramiocel/cZduNXsRIad">earnings</a> call, CEO Linda Marban <a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-best-week-month-ceo-rules-out-conditional-deramiocel-approval/cZdDdk4RIa1">rejected</a> the possibility that the Deramiocel therapy could receive only a conditional regulatory decision. The U.S. Food and Drug Administration is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">Wall Street Take Aways</h2>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on today's selloff. The 8% pullback is a "transient, healthy and short-lived market correction" following the rally post FDA acceptance of Capricor's application of Deramiocel for the treatment of Duchenne muscular dystrophy, the analyst told investors in a research note. Roth would be buying today's "dislocation" and expects the share price to move towards its price target of $41. The firm has a ‘Buy’ rating on Capricor.B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares. The analyst said that its confidence has increased in a potential smooth approval path for Deramiocel ahead of the August 22 decision date, with shares expected to build into the decision as investors digest additional dataset, the analyst told investors in a research note.Piper Sandler raised the firm's price target on CAPR to $58 from $45 and kept an ‘Overweight’ rating on the shares. The firm noted Capricor ended 2025 with cash of $318 million to fund operations through 2027. The FDA has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22. Optimistically, the label could include the broad Duchenne muscular dystrophy population, not just DMD cardiomyopathy, Piper argues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained 138% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-will-delay-release-of-cybercab-until-late-2026-owing-to-safety-issues-fund-manager-predicts/cZdDVgaRIO9">Tesla Will Delay The Release Of Cybercab Until Late-2026 Owing To Safety Issues, Fund Manager Predicts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval

On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval.

Equity

B. Riley Financial Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price

B. Riley Financial raised their price target on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the stock a "buy" rating in a report on Friday...

Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates

Capricor Therapeutics shares are trading lower Friday afternoon after the biotech company reported a wider-than-expected fourth-quarter loss.read more...

Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.3% - Time to Sell?

Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6.3% - Should You Sell...

Capricor Therapeutics (NASDAQ:CAPR) Given Overweight Rating at Piper Sandler

Piper Sandler reaffirmed an "overweight" rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday...

Pier Capital LLC Boosts Stock Position in Capricor Therapeutics, Inc. $CAPR

Pier Capital LLC increased its holdings in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 35.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund...

<ul class="summary-bullets"><li>CEO Linda Marban dismissed concerns that Deramiocel would receive a conditional approval, citing a trial that met both primary and key secondary endpoints.</li><li>The company is preparing for a potential launch, with its San Diego manufacturing capable of initially treating about 250 patients per year.</li><li>Capricor reported a wider-than-expected Q4 loss of $0.62 per share and no revenue, but ended 2025 with about $318.1 million in cash.</li></ul>Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban has pushed back on regulatory doubts around its Duchenne Muscular Dystrophy (DMD) therapy Deramiocel, saying there is “no way” the drug ends up with only a conditional FDA approval, providing some<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is heading for its best week since Feb. 20.<h2 class="st-heading-2">CEO Rejects Conditional Approval Risk For Deramiocel</h2>On the company’s fourth-quarter (Q4) earnings call, CEO Linda Marban rejected the possibility that the therapy could receive only a conditional regulatory decision. “No. There’s no way this would be a conditional approval,” Marban said, noting that the trial supporting the application was a randomized, double-blind, placebo-controlled study that met its primary endpoint as well as key secondary endpoints.The comments came after the U.S. Food and Drug Administration (FDA) accepted Capricor’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-dmd-therapy-phase3-heart-function-results/cZdu4NvRI9m">resubmitted</a> biologics license application for Deramiocel, setting a PDUFA decision date of Aug. 22.&nbsp;Capricor is seeking full approval of Deramiocel for Duchenne muscular dystrophy (DMD) and expects the data to support labeling that reflects benefits in both skeletal muscle and heart disease associated with the condition.<h2 class="st-heading-2">Launch Preparations Underway</h2>The company is also preparing for commercialization if the therapy wins regulatory clearance. Capricor’s San Diego GMP manufacturing facility has already completed its FDA pre-license inspection and is positioned to support an initial commercial launch. The site currently has&nbsp;the capacity to treat about 250 patients per year.Marban said the company plans to begin stockpiling commercial doses once labeling discussions with the FDA are finalized, signaling confidence in the potential approval.Capricor is also expanding manufacturing capacity with additional clean rooms at the same facility, which the company expects could increase production to roughly 2,500 patients per year once fully operational.<h2 class="st-heading-2">Clinical Data Supporting Approval</h2>Deramiocel’s application is supported by results from the Phase 3 Hope-3 trial, which met its primary endpoint measuring upper-limb function and key cardiac endpoints in patients with Duchenne muscular dystrophy. Additional data presented&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-dmd-therapy-phase3-heart-function-results/cZdu4NvRI9m">this week</a> showed reduced cardiac fibrosis and improvements in functional measures tied to daily activities.Marban said physician sentiment around the therapy has strengthened following the new data. “Physicians who before were hopeful are now convinced,” she said, adding that the company is receiving increasing inquiries about prescribing and availability.<h2 class="st-heading-2">CAPR Q4 Review</h2>Capricor reported a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-dmd-therapy-phase3-heart-function-results/cZdu4NvRI9m">Q4 loss</a> of $0.62 per share, wider than analysts’ estimate of a $0.55 loss per share. The company reported nil revenue, compared with about $11.1 million a year ago, as milestone payments tied to its partnership with Nippon Shinyaku had already been fully recognized.The company ended 2025 with about $318.1 million in cash, which will fund operations into late 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CAPR was ‘extremely bullish’ amid over a 700% surge in message volumes over the past month.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_4b733f342d.webp" alt="capr ss.png" width="971" height="145"><figcaption>CAPR sentiment and message volume as of March 13 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/RaymondBabbitt/message/647418188">said</a>, “Congratulations to the Bulls, and to the patients who have been waiting for a miraculous discovery to treat their illness of DMD - Deramiocel, is just around the corner.”<stembedurl>https://stocktwits.com/RaymondBabbitt/message/647418188</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Bentradez/message/647424625">said</a> interest in Deramiocel was strong, noting that participants are expected to join quickly and that others have been reaching out to try to take part, adding that “the demand is there for sure.”<stembedurl>https://stocktwits.com/Bentradez/message/647424625</stembedurl>The stock has surged over 150% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval

The FDA has accepted Capricor’s resubmitted biologics license application, setting an Aug. 22 PDUFA decision date for Deramiocel in DMD. 

<ul><li>The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million.</li><li>Capricor is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22.</li><li>The FDA reversed course on its previous rejection for Deramiocel earlier this week.</li></ul>&nbsp;Shares of Capricor Therapeutics (CAPR) slid down about 2% after-hours on Thursday, after the company reported wider-than-expected quarterly loss, partially offset by optimism for the company’s pipeline.For the fourth quarter, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/340/capricor-therapeutics-reports-fourth-quarter-and-full-year">reported</a> a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024, and more than a Wall Street estimate of a loss of $0.54.The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million. The company now believes this to be sufficient to cover anticipated expenses and capital requirements though 2027.<h2 class="st-heading-2">Optimism For Deramiocel Application</h2>The company is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22. If approved, the company said that its San Diego GMP manufacturing facility will support a potential commercial launch.“Capricor enters 2026 with important regulatory and clinical momentum as we work toward potential approval of Deramiocel for the treatment of Duchenne muscular dystrophy (DMD),” said Linda Marbán, CEO of Capricor.The FDA is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock stayed within ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained about 156% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fly-stock-rallies-on-wall-street-spiking-optimism-after-succesful-alpha-launch/cZdujXtRIaP">FLY Stock Rallies On Wall Street’s Spiking Optimism After Successful Alpha Launch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy

For the fourth quarter, the company reported a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024.

Capricor Therapeutics Q4 Earnings Call Highlights

Capricor Therapeutics (NASDAQ:CAPR) executives used the company's fourth-quarter and full-year 2025 earnings call to outline progress toward a potential U.S. approval of deramiocel for Duchenne...

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Current Price	$28.90
Prev Close	$29.95
Open	$29.62
Dividend Yield	0.00%
50-Day Moving Average	$26.76
Beta	1.16
Avg. Volume	1.09M
PE Ratio	-12.81

52-Week High	$40.37
52-Week Low	$4.30
Market Capitalization	$1.66B
EPS (Annual)	-$2.26
Price to Book	5.42
Revenue Per Employee	$0.00

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CAPR News

CAPRCapricor Therapeutics Inc